Skip to main content
Silvio Inzucchi, MD, Endocrinology, New Haven, CT, Yale-New Haven Hospital

SilvioEdwardInzucchiMD

Endocrinology • New Haven, CT

Adrenal Disease, Diabetes, Pituitary Disorders & Neuroendocrinology

Professor of Medicine, Yale University

Join to view full profile

Dr. Inzucchi is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Inzucchi's full profile

Already have an account?

Education & Training

  • Yale-New Haven Medical Center
    Yale-New Haven Medical CenterFellowship, Endocrinology, Diabetes, and Metabolism, 1992 - 1994
  • Yale-New Haven Medical Center
    Yale-New Haven Medical CenterResidency, Internal Medicine, 1985 - 1987
  • Harvard Medical School
    Harvard Medical SchoolClass of 1985

Certifications & Licensure

  • CT State Medical License
    CT State Medical License 1987 - 2024
  • American Board of Internal Medicine Internal Medicine

Awards, Honors, & Recognition

  • America's Top Doctors Castle Connolly, 2008-2014
  • New York Magazine: Top Doctors Castle Connolly, 2007-2014
  • Top Doctors: New York Metro Area Castle Connolly, 2006-2014
  • Join now to see all

Publications & Presentations

PubMed

Journal Articles

  • Empagliflozin and Kidney Function Decline in Patients with Type 2 Diabetes: A Slope Analysis from the EMPA-REG OUTCOME Trial  
    Silvio Inzucchi, MD, Journal of the American Society of Nephrology
  • Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients  
    Erin A Bohula, Stephen D Wiviott, Benjamin M Scirica, Darren K McGuire, Marc S Sabatine, Marc P Bonaca, Christian T Ruff, Silvio E Inzucchi, The New England Journal of Medicine
  • Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients  
    Christina L. Fanola, Darren K. McGuire, Silvio E. Inzucchi, Erin A. Bohula, The New England Journal of Medicine

Lectures

  • Reduction in Albuminuria with Dapagliflozin Cannot Be Predicted by Baseline Clinical Characteristics or Changes in Most Other Risk Markers 
    Scientific Sessions 2008, New Orleans, Louisiana, USA
  • Reduction in Albuminuria with Dapagliflozin Cannot Be Predicted by Baseline Clinical Characteristics or Changes in Most Other Risk Markers 
    Scientific Sessions 2010, Chicago, Illinois, USA
  • Reduction in Albuminuria with Dapagliflozin Cannot Be Predicted by Baseline Clinical Characteristics or Changes in Most Other Risk Markers 
    American Heart Association, Scientific Sessions 2010, Chicago, Illinois, USA
  • Join now to see all

Other

Press Mentions

  • SGLT2 Inhibitors Cut AFib Risk in Real-Word Analysis
    SGLT2 Inhibitors Cut AFib Risk in Real-Word AnalysisJune 13th, 2022
  • Explaining Insulin Resistance, and How to Reverse It
    Explaining Insulin Resistance, and How to Reverse ItOctober 25th, 2021
  • Does Coffee Count as Fluid?
    Does Coffee Count as Fluid?August 9th, 2021
  • Join now to see all

Grant Support

  • GRADE TrialNIDDK2013–2020
  • IRIS TrialNINDS2004–2016
  • Dosage According To IGF1 Response In Growth Hormone DefiNational Center For Research Resources2000–2001
  • Effects Of Troglitazone And Metformin On Glucose MetabolismNational Center For Research Resources1996–1999
  • Ovine CRH In Evaluation Of Cushing SyndromeNational Center For Research Resources1997
  • Endocrine Evaluation Of Patients With Diseases Of The PituitaryNational Center For Research Resources1996–1997
  • Effects Of Growth Hormone Replacement In GH Deficient AdultsNational Center For Research Resources1996

Professional Memberships

Hospital Affiliations

Dr. Silvio Inzucchi, Dr. Silvio Inzucchi, MD, Dr. S Inzucchi, Dr. Silvio Edward Inzucchi